Research programme: viral fusion inhibitors - Array BioPharma/Trimeris

Drug Profile

Research programme: viral fusion inhibitors - Array BioPharma/Trimeris

Alternative Names: HIV fusion inhibitors research programme - Array BioPharma/Trimeris; RSV fusion inhibitors research programme - Array BioPharma/Trimeris

Latest Information Update: 19 Mar 2008

Price : $50

At a glance

  • Originator Array BioPharma; Trimeris
  • Class Small molecules
  • Mechanism of Action HIV fusion inhibitors; Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued HIV infections; Respiratory syncytial virus infections

Most Recent Events

  • 19 Mar 2008 Discontinued - Preclinical for Respiratory syncytial virus infections in USA (unspecified route)
  • 19 Mar 2008 Discontinued - Preclinical for HIV infections in USA (unspecified route)
  • 12 Jun 2006 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top